On Tuesday's edition of Market Checkup, Motley Fool health-care analyst David Williamson takes a look at the biggest winners and losers in health care stocks today.
Shares of Cambrex Corporation (CBM +0.00%) soared Tuesday, up 15% for the day. News on Monday broke that the company recently passed an FDA manufacturing inspection for its plant in Iowa, and today the stock was upgraded to "overweight" by a company called First Analysis, because of increased confidence that the company would close a large API manufacturing deal with Gilead (GILD 1.76%) for its hepatitis C drug Sovaldi. There is also the belief that Gilead would give Cambrex preference for future drug opportunities.
In this segment, David discusses why this deal could be a huge deal for the company, and why, when he started digging into Cambrex, he liked what he saw.
